San Francisco, CA – November 10, 2014 – CollabRx, Inc. (NASDAQ: CLRX) today announced a partnership with Cartagenia, Inc. to provide and promote to the clinical laboratory market an end-to-end software solution to support clinicians and pathologists with clinical genetic testing and reporting in oncology, including next-generation sequencing (NGS) -based tests. Cartagenia is a leader in providing genetics labs and clinicians with software-based workflow support for variant assessment support, lab reporting, and integration of clinical knowledge-bases. Combined with CollabRx’s industry-leading decision support solutions in oncology, the partnership will enable clinical and pathology laboratories to generate automated workflows allowing them to quickly and efficiently analyze and report on NGS test results in cancer by providing integrated access to CollabRx’s highly credible medical and scientific knowledge with their own proprietary information to create physician- ready reports.
Under terms of the agreement, CollabRx’s Genetic Variant Annotation (GVA) Service™ will be integrated with Cartagenia’s Bench for Oncology software platform. This capability will allow clinical laboratories to keep up with the scale and pace of change in medical and scientific knowledge associated with NGS cancer panels and use this knowledge to support ordering physicians in patient treatment planning by providing clear and easy-to-understand reports that associate genetic alterations with therapy options. CollabRx and Cartagenia will promote the partnership by cooperating on marketing-related initiatives with the goal of increasing customer recognition of the benefits and advantages of the joint use of each company’s products.
“CollabRx’s scientists and physicians, together with their large network of clinical advisors, have thought deeply about curating and annotating medical genomics knowledge to support decision making by physicians who wish to consider a tumor’s genetic profile in optimizing a treatment plan for their cancer patients,” said Steven Van Vooren, one of Cartagenia’s scientific founders. “This careful consideration is necessary given the complexity and fast-changing nature of medical and scientific research in cancer genomics. We are highly enthusiastic about working with CollabRx to enable clinical laboratories to access the CollabRx GVA Service through Cartagenia’s Bench for Oncology software platform.”
“Cartagenia has developed an industry-leading software platform that has been adopted by leading clinical laboratories that value automation in report generation in combination with tools that allow them to access, review and validate high quality knowledge to support the interpretation of results of NGS-based tests in cancer,” said Thomas Mika, Chairman, President and CEO of CollabRx. “We are excited to partner with Cartagenia to provide a robust, integrated medical informatics solution to the clinical laboratory market in the U.S. and Europe.”
CollabRx and Cartagenia representatives will be available to discuss this partnership at the 2014 Association for Molecular Pathology (AMP) Annual Meeting taking place November 12-15, 2014 in National Harbor, MD.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About the CollabRx GVA Service
The GVA Service offered by CollabRx is a widely used, highly scalable, and cloud-based electronic decision support system that provides a turn-key analysis of many types of genetic alterations in cancer. The GVA Service accepts genetic data from any source or platform and pairs it with information contained in a knowledge base that includes the clinical impact of specific genetic profiles. The CollabRx knowledge base is supported by a proprietary technology platform and expert system that leverages a large and growing network of over 75 thought-leaders and clinical practitioners in the United States and Europe who work together with CollabRx to develop new tools for clinical decision-making in oncology. The GVA Service is offered to customers in a Software as a Service (SaaS) business model.
Cartagenia supplies diagnostic support software, database systems, and related services to genetic labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counseling.
Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.
The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.
Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Gavin J. Gordon, MBA, PhD
Vice President of Business Development & Strategic Alliances
Dian Griesel Int’l.
Laura Radocaj- media
Cheryl Schneider- investors
+32 16 40 40 66